Beam Therapeutics Inc.
NASDAQ: BEAM0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- John Evans
- Employees
- 393
- Headquarters
- Cambridge, United States
- IPO year
- 2020
- Market cap
- $3.5B
- Website
- https://www.beamtx.com
Loading BEAM…
Loading profile data…Frequently asked questions about BEAM
What does Beam Therapeutics Inc. (BEAM) do?
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BE...
Where does BEAM trade?
Beam Therapeutics Inc. (BEAM) trades on the NASDAQ Global Select.
What sector is BEAM in?
Beam Therapeutics Inc. (BEAM) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Beam Therapeutics Inc.?
John Evans is the chief executive officer of Beam Therapeutics Inc. (BEAM).
Where is Beam Therapeutics Inc. headquartered?
Beam Therapeutics Inc. is headquartered in United States.
Does BEAM pay a dividend?
Beam Therapeutics Inc. (BEAM) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BEAM go public?
Beam Therapeutics Inc. (BEAM) completed its initial public offering in 2020.